Please assess the completion status of the following clinical trial:

Trial Title: Use of the Ulcerative Colitis Diet for Induction of Remission

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent~* Established diagnosis of UC disease.~* Age: 5 - 18 years ( inclusive)~* Mild to moderate active disease, 10 ≤ PUCAI ≤45.~* Stable medication (IMM/ 5ASA) use for the past 6 weeks.~* For patients who received antibiotic treatment: age 10-18 (inclusive).~Exclusion Criteria:~* Any proven infection such as positive stool culture, parasite or C.difficile.~* Use of Antibiotics~* Use of steroids in the previous two weeks only~* Patients that are refractory to full dose steroids ( 1 mg/kg/day)~* Past acute severe UC.~* Current Extra intestinal manifestation of UC.~* Pregnancy.~A subset of patients who are on steroids and relapse during steroids treatment ≤0.5 mg/kg with mild to moderate disease activity will act as a second subset for this exploratory study.~-

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Ulcerative Colitis Diet counseling (Type: EXPERIMENTAL): Patients will receive a structured novel diet termed the UCD for 6 weeks. . patients that completed induction phase with remission(PUCAI\<10) will be asked if they are willing to adhere to the UCD for an additional 20 weeks.
- Antibiotic Treatment (Type: EXPERIMENTAL): Patients failing to enter or maintain remission by 6 weeks, or with worsening disease at any time after week 2 will be considered failures on an intention to treat basis. Eligible patients at this time at aged 10 or above may receive a 14 day antibiotic course with Doxycycline, amoxicillin and metronidazole.In addition to the description above children who refused to UCD or with low adherence to UCD may be enrolled directly to this arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).